Eficacia del uso de entresto como esquema terapéutico en pacientes con insuficiencia cardiaca crónica en el Hospital Teodoro Maldonado Carbo durante el año 2018 – 2021.

Abstract

Chronic heart failure is a pathology that generates high mortality, especially in older patients and with different comorbidities regardless of ejection fraction, due to this other types of drugs have been developed that seek to be the alternative to patients whose treatment has failed with IECCA and ARA II, this drug Entresto composed of Sacubitril/Valsartan inhibits neprilysin and the angiotensin II receptor, and has shown positive results in studies in reducing hospitalizations and mortality from heart failure with reduced ejection fraction. In the present study carried out at the Teodoro Maldonado Carbo Hospital from 2018- 2021, 70 patients who are using Entrestos as a therapeutic regimen in the control of heart failure were taken as a sample, taking into account variables such as ejection fraction, sex, age , blood pressure, ethnicity, socioeconomic level, obtaining as a result that in relation to ejection fraction, it was found that 47% of the study subjects had an ejection fraction between 30-40%, followed by patients with ejection fraction 41-51% corresponding to 33% of the population, while patients with an ejection fraction greater than 33% would occupy the third position, 10%, thus demonstrating regularization in the ejection fraction of patients using Entrestos. With respect to sex, a higher prevalence was observed in female patients in 69% as opposed to men in 31% and in relation to age it was shown that 54% of patients between 46-70 years old suffer from this pathology in comparison of 39% patients older than 71 years and 7% younger than 45 years. People taking Entrestos were shown to maintain controlled blood pressure by 61%. In relation to ethnicity, mestizos predominated in 70% compared to 10% of white race and 14% of African descent, affecting 84% of patients with a medium socioeconomic level. In conclusion, patients who received treatment with Entrestos in their treatment for chronic heart failure showed greater efficacy in their ejection fraction of 30-40% and blood pressure in the first degree, a higher prevalence was observed in women of mixed race between 46 -70 years with medium socioeconomic level.